Learning hub

Σχετικά με τα μέλη της κοινοπραξίας Konstantinidis Dimitrios CERTH Position Postdoctoral researcher What is your role in iPROLEPSIS? Researcher and technical developer What are your main activities in the project? I am mainly involved in the research activities of CERTH, concerning psoriatic nail detection and classification, range-of-motion assessment through the execution of active video tests and nutrition and physical activity recommendations. What is your motivation? I am deeply passionate about artificial intelligence and deep learning, with a strong interest in uncovering hidden patterns within data that can lead to highly accurate and reliable predictions. I find great satisfaction in developing advanced machine learning techniques to transform data into innovative solutions that contribute to real-world progress. Nikos Melanitis Ainigma Position Data Scientist What is your role in iPROLEPSIS? Data Scientist, Digital health and predictive modelling What are your main activities in the project? To design and implement novel approaches for improved management of PsA, through personalized models that warn patients for high risk of PsA exacerbation (flare). What is your motivation? To be part of the digital innovation in Health, enabling better disease management and personalised, precision medicine. Kosmas Dimitropoulos CERTH Position Principal Researcher (Researcher of Grade B’) What is your role in iPROLEPSIS? Principal Investigator for CERTH What are your main activities in the project? I am mainly involved in the research activities of CERTH, concerning psoriatic nail detection and classification, range-of-motion assessment through the execution of active video tests and nutrition and physical activity recommendations. What is your motivation? I am deeply motivated by the intersection of Artificial Intelligence and healthcare. I aspire to contribute to research that applies deep learning techniques to personalized medicine, enabling more accurate, data-driven, and patient-specific approaches to diagnosis and treatment. Eleni Vasileiou Signal Processing & Biomedical Technology Unit (SPBTU) – Aristotle University of Thessaloniki (AUTH) Position Research assistant working on digital health technologies and AI-enabled healthcare tools What is your role in iPROLEPSIS? AI Researcher & Data Scientist | Digital health and predictive modelling What are your main activities in the project? My main activities focus on developing digital, passively captured indicators that support risk prediction and monitoring models for psoriatic arthritis. I work on digital phenotyping of inflammatory symptoms with an emphasis on tracking motor manifestations using smart devices and wearables. This involves designing methods to analyze data from daily living activities – such as sleep, walking, and hand movements – to capture subtle physiological and behavioral changes associated with disease onset and progression. These efforts aim to identify key drivers of psoriatic arthritis and support personalized models for disease risk, progression prediction, and inflammation monitoring. What is your motivation? I am deeply motivated by the potential of digital health technologies to bring a more human and data-informed approach to healthcare. By combining AI with continuous, real-world data, we can reveal patterns often hidden in traditional clinical assessments. What drives me is the belief that these insights can empower both patients and clinicians to make earlier and more informed decisions, ultimately improving health outcomes and quality of life. My goal is to contribute to a future where technology enhances understanding, prevention, and personalized care for chronic conditions. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

iProlepsis psoriatic arthritis project is a comprehensive multiscale model employing novel trustworthy AI-based analysis of multisource and heterogenous data. Στόχοι του έργου iPROLEPSIS και πακέτα εργασίας Το έργο φιλοδοξεί να ρίξει φως στη μετάβαση από υγιή κατάσταση σε ΨΑ με ένα ολοκληρωμένο πολλαπλής κλίμακας/πολυπαραγοντικό μοντέλο χρησιμοποιώντας καινοτόμα έμπιστη (trustworthy) ανάλυση βασισμένη στη τεχνητή νοημοσύνη χρησιμοποιώντας πολλαπλών πηγών και ετερογενών δεδομένα (όπως περιβαλλοντολογικά, γενετικά, και συμπεριφορικά). Στόχοι έργου Η κοινοπραξία iPROLEPSIS εργάζεται σε 7 φιλόδοξους βασικούς στόχους στον τομέα της Ψωριασικής Αρθρίτιδας (ΨΑ). Παράγοντες φλεγμονής σχετικοί με συμπτώτης της ΨΑ Ανακάλυψη των παραγόντων φλεγμονής PsA από δεδομένα υγείας, περιβάλλοντος και omics μέσω τεχνικών τεχνητής νοημοσύνης για την εξόρυξη δεδομένων. Ο ρόλος των μαστοκυττάρων Διερευνήστε τον ρόλο των μαστοκυττάρων και των χαρακτηριστικών από τη μη επεμβατική μικροαγγειακή/αρθρική απεικόνιση του δέρματος στην παρακολούθηση των φλεγμονωδών συμπτωμάτων. Εξατομικευμένες παρεμβάσεις Ανάπτυξη εξατομικευμένων παρεμβάσεων βασισμένων σε ψηφιακά μέσα για τη διατήρηση ή ακόμα και τη βελτίωση της ποιότητας ζωής. Συνδημιουργικό οικοσύστημα Συνδημιουργία του οικοσυστήματος iPROLEPSIS με συμμετοχή κύριων ενδιαφερόμενων φορέων, ακολουθώντας τις αρχές της ηθικής, συμπεριληπτικής και έμπιστης τεχνητής νοημοσύνης. Ψηφιακοί βιοδείκτες Ανάπτυξη και επικύρωση αντικειμενικών ψηφιακών βιοδείκτων για την παρακολούθηση των φλεγμονωδών συμπτωμάτων και της δραστηριότητας της νόσου. Έμπιστα (trustworthy) μοντέλα τεχνητής νοημοσύνης Δημιουργία έμπιστων μοντέλων τεχνητής νοημοσύνης για εξατομικευμένη πρόβλεψη κινδύνου εκδήλωσης ΨΑ, έγκαιρη διάγνωση και πρόγνωση καταστάσεων υψηλής δραστηριότητας της νόσου. Ψηφιακό οικοσύστημα υγείας Ανάπτυξη και κλινική επικύρωση του ψηφιακού οικοσύστηματος iPROLEPSIS για να την ενδυνάμωση των ατόμων με ΨΑ ή σε κίνδυνο εκδήλωσης ΨΑ και τους επαγγελματίες υγείας. Πακέτα εργασίας Τα 6 πακέτα εργασίας του έργου θα συγκεντρώσουν διαφορετικές και συμπληρωματικές εξειδικεύσεις από εταίρους της κοινοπραξίας. WP1 WP2 WP3 WP4 WP5 WP6 Πακέτο εργασίας 1: Διαχείριση και συντονισμός Το ΠΕ1 αφιερώνεται στη διαχείριση και τον συντονισμό του έργου με στόχο να επιτρέψει την ομαλή ροή εργασιών του έργου. Διασφάλιση της βέλτιστης συμβατικής, διοικητικής, οικονομικής, επιστημονικής, τεχνικής διαχείρισης, διαχείρισης πνευματικών δικαιωμάτων και καινοτομίας· Διασφάλιση την ποιότητα του έργου και προστατέψτε τη δεοντολογία, τη συμμόρφωση με τους κανονισμούς και τη σωστή διαχείριση δεδομένων. Πακέτο εργασίας 2: Εξόρυξη γνώσης, θεμελίωση και συμμετοχικός σχεδιασμός Το ΠΕ2 στοχεύει στη δημιουργία ενός θεμελιώδους σώματος γνώσεων σχετικά με την ΨΑ, τις συνδεδεμένες συνθήκες και τη φλεγμονή· Προσδιορισμός, ανάκτηση και επιμέλεια συνόλων δεδομένων που σχετίζονται με δραστηριότητες Ε&Α του έργου. Προσδιορισμός των ανάγκων των χρηστών και αποτελεσματική συνεργασία με βασικά ενδιαφερόμενα μέρη για την καθοδήγηση ερευνητικών ερωτημάτων και τη συνδημιουργία των εργαλείων ψηφιακής φροντίδας iPROLEPSIS. Θεμελίωση και παρακολούθηση πρακτικών για τη διασφάλιση της τήρησης των βασικών αρχών έμπιστης τεχνητής νοημοσύνης (trustworthy artificial intelligence) στο iPROLEPSIS. Πακέτο εργασίας 3: Έρευνα για παράγοντες φλεγμονής σχετικού με την ΨΑ και παρακολούθηση Το ΠΕ3 είναι αφιερομένο στον εντοπισμό παραγόντων που σχετίζονται με την ΨΑ και την σχετική φλεγμονή, αξιοποιώντας νέα και υπάρχοντα δεδομένα υγείας από πολλαπλές πηγές. Στην ανάπτυξη ψηφιακών βιοδεικτών (digital biomarkers, dBMs) που υλοποιούνται μέσω έξυπνων και φορετών συσκευών (smartphone/wearable) για την αξιολόγηση των φλεγμονωδών συμπτωμάτων της ΨΑ. Στο να ρίξει φως στις αλλαγές στις αρθρώσεις και στη μικροαγγείωση του δέρματος που σχετίζονται με την ΨΑ και στον ρόλο των μαστοκυττάρων στη σχετική φλεγμονή. Μέσω της συγχώνευσης δεδομένων, στο να αναπτυχθεί ένα πολλαπλής κλίμακας/πολυπαραγοντικό μοντέλο ΨΑ, δίνοντας έμφαση στην πρόβλεψη της μετάβασης ατόμων υψηλού κινδύνου και ασθενών με ψωρίαση σε ΨΑ, και στην πρόβλεψη μετάβασης σε προχωρημένη φλεγμονώδη κατάσταση ασθενών με ΨΑ. Πακέτο εργασίας 4: Ανάπτυξη του ψηφιακού οικοσυστήματος υγείας iPROLEPSIS για εξατομικευμένη προληπτική φροντίδα Το ΠΕ4 αφορά τις εργασίες καθορισμού των τεχνικών προδιαγραφών του οικοσυστήματος iPROLEPSIS και της ανάπτυξης μιας ισχυρής υποδομής διαχείρισης δεδομένων και μίας πλατφόρμας DevOps/MLOps· Μέσω μιας ευέλικτης προσέγγισης, την ανάπτυξη του ελάχιστα βιώσιμου προϊόντος (minimum viable product, MVP) iPROLEPSIS για την εξατομικευμένη φροντίδα ασθενών με ΨΑ, συμπεριλαμβανομένων: 1) μίας εφαρμογής για τους ασθενείς που ενσωματώνει μοντέλα (βασισμένα σε ψηφιακούς βιοδείκτες) για την παρακολούθηση της ΨΑ, στοχευμένες παρεμβάσεις και προσαρμοσμένες συστάσεις για τον τρόπο ζωής με γνώμονα την τεχνητή νοημοσύνη, 2) μία σουίτα σοβαρών παιχνιδιών (serious games) για υγεία και ευεξία, 3) μία εφαρμογή για επαγγελματίες υγείας που θα τους επιτρέπει να παρακολουθούν εξ' αποστάσεως τους ασθενείς και να βλέπουν προβλέψεις για την πορεία τους. Πακέτο εργασίας 5: Κλινικές μελέτες Στο ΠΕ5 θα αναπτυχθούν τα πρωτόκολλα των κλινικών μελέτων και θα πραγματοποιηθούν οι διαδικασίες έγκαιρης έγκρισής τους από τους αρμόδιους φορείς· Δημιουργία συστήματος για τον συντονισμό της ένταξης των ασθενών, την ορθή διαχείριση κλινικών των δεδομένων και την τεκμηρίωση.· Οργάνωση και διεξαγωγή τεσσάρων κλινικών μελετών: δύο πολυκεντρικές προοπτικές μελέτες κοόρτης για ανακάλυψη και επικύρωση παραγόντων φλεγμονής και ψηφιακών βιοδεικτών που σχετίζονται με την ΨΑ, μία μελέτη παρατήρησης της ΨΑ και τις αλλαγές στις αρθρώσεις και στο μικροαγγειακό σύστημα του δέρματος και μία πολυκεντρική τυχαιοποιημένη ελεγχόμενη δοκιμή (RCT) για την απόδειξης της ιδέας (proof-of-concept) και αξιολόγηση της αποτελεσματικότητας των εργαλείων ψηφιακής φροντίδας iPROLEPSIS. Πακέτο εργασίας 6: Διάδοση, επικοινωνία και εκμετάλλευση Το ΠΕ6 θα μεγιστοποιήσει την προβολή του έργου και των αποτελεσμάτων του και θα διευκολύνει την ανταλλαγή γνώσεων, ενώ θα εμπλέξει ένα ευρύ δίκτυο ενδιαφερομένων. Ανάπτυξη εκπαιδευτικού περιεχομένου που σχετίζεται με την ΨΑ; Καθορισμός ένος οδικού χάρτη για τη ρυθμιστική έγκριση των ψηφιακών εργαλείων iPROLEPSIS. Εκτέλεση μιας ενδελεχούς κοινωνικο-οικονομικής ανάλυσης και μίας ανάλυσης της αγοράς και την συγγραφή σχέδιων εκμετάλλευσης. ΟΡΑΜΑ ΕΡΓΟΥ

Lerning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is psoriatic arthritis? Take a Quiz What are the symptoms of psoriatic arthritis? Take a Quiz How is psoriatic arthritis treated? Drug treatments Take a Quiz How is psoriatic arthritis treated? Self-care and lifestyle Take a Quiz How will psoriatic arthritis affect me? Sleep and Fatigue Take a Quiz How will psoriatic arthritis affect me? Relationships and Family Planning Take a Quiz What causes psoriatic arthritis? Take a Quiz How is psoriatic arthritis diagnosed? Take a Quiz How is psoriatic arthritis treated? Non-pharmacological treatments Take a Quiz How will psoriatic arthritis affect me? Work Take a Quiz How will psoriatic arthritis affect me? Emotional wellbeing Take a Quiz

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Introduction Learning how to live with psoriatic arthritis might feel like a challenge, especially at first. But understanding your diagnosis and how to manage this chronic disease can help you take control of your health. Psoriatic arthritis patient booklet is meant to help you understand your disease and medications, and to improve your ability to communicate your symptoms and concerns to your healthcare professionals. Here, you will also find several non-pharmacological strategies that may ease your symptoms and help you to cope with this disease (e.g., physical exercise, sleeping habits, and diet). This booklet has been edited by rheumatologists, healthcare experts, and patients living with psoriatic arthritis. The information in this booklet is for educational purposes only, and it should never replace the information and advice from your treating physician(s). It is meant to inform the discussions that you have with healthcare professionals, as well as others who play a role in your care and well-being. What is psoriatic arthritis? Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis. Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time. Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in three forms: oligoarticular arthritis that affects four or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves five or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. Learn about psoriatic arthritis Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 The Psoriatic Arthritis Patient Handbook is now available for download. The booklet includes essential information to support your understanding of psoriatic arthritis and offers practical tips to enhance your daily life.

The consortium of iProlepsis project for psoriatic arthritis consists of 15 partners from 9 countries. Discover more about project by visiting our website. Σχετικά με τα μέλη της κοινοπραξίας Συντονιστής του έργου iPROLEPSIS Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης Η κοινοπραξία αποτελείται από 15 συνεργάτες από 9 χώρες. Μέλη της κοινοπραξίας iPROLEPSIS

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. Όραμα και μεγιστοποίηση του αντίκτυπου του έ ργου iPROLEPSIS Η πρόβλεψη της μετάβασης από υγιή κατάσταση σε ψωριασική αρθρίτιδα μέσω ανάλυσης δεδομένων από πολλαπλές πηγές με χρήση ενός νέου εξατομικευμένου ψηφιακού οικοσυστήματος φροντίδας και τη μεγιστοποίηση του αντίκτυπου με το άνοιγμα, την ορατότητα, τη δικτύωση και την επαναχρησιμοποίηση των παραγόμενων προϊόντων. Όραμα του έργου Ανάλυση δεδομένων, στόχοι του έργου, τεχνολογίες IoT και εφαρμογή κινητών συσκευών. Σχετικά με την Ψωριασική Αρθρίτιδα Η ψωριασική αρθρίτιδα (ΨΑ) είναι μια χρόνια, φλεγμονώδης νόσος, που προσβάλλει τον σκελετό των άκρων και του κορμού, με σοβαρές επιπτώσεις στην ποιότητα ζωής των ασθενών. Υπολογίζεται ότι το 1-2% του γενικού πληθυσμού πάσχει από ψωριασική αρθρίτιδα, δηλαδή 5 έως 10 εκατομμύρια άνθρωποι στην ΕΕ επηρεάζονται. Η ψωριασική αρθρίτιδα σχετίζεται με την ψωρίαση. Εως και το 30% των ατόμων που ζουν με ψωρίαση, δηλαδή τουλάχιστον 100 εκατομμύρια άνθρωποι παγκοσμίως (WHO), αναμένεται να εκδηλώσουν την ασθένεια. Ο στόχος Ο στόχος του iPROLEPSIS είναι να προτείνει ένα νέο οικοσύστημα που περιλαμβάνει μηχανισμούς συλλογής δεδομένων πραγματικού κόσμου (real-world data, RWD) και ένα ισχυρό σύστημα υποστήριξης αποφάσεων για την παροχή νέας γνώσης για τους βασικούς παράγοντες που επηρεάζουν τη μετάβαση από υγιή κατάσταση σε ψωριασική αρθρίτιδα, υιοθετώντας μια πολλαπλής κλίμακας και πολυπαραγοντική προσέγγιση, ώστε, σε συνδυασμό πρακτικών επεξηγηματικής τεχνητής νοημοσύνης (explainable AI, xAI), να προσφέρουμε ένα αποτελεσματικό, αποδοτικό και κλινικά επικυρωμένο εξατομικευμένο οικοσύστημα ψηφιακής φροντίδας για ασθενείς με ψωριασική αρθρίτιδα. Τεχνολογίες Τεχνολογίες αισθητήρων IoT (Internet of Things) και μια εφαρμογή για κινητές συσκευές θα βρίσκονται στο επίκεντρο της διαδικασίας συλλογής δεδομένων πραγματικού κόσμου (real-world data, RWD), ενώ δεδομένα αναδρομικών και προοπτικών μελετών θα συλλεχθούν από τις βάσεις δεδομένων των κλινικών συνεργατών και θα συνδυαστούν με αντίστοιχα δεδομένα ανοιχτής πρόσβασης. Μέσω της ανάλυσης και της οπτικοποίησης αυτών των δεδομένων χρησιμοποιώντας μοντέλα τεχνητής νοημοσύνης και ένα εργαλείο οπτικής ανάλυσης, αντίστοιχα, το iPROLEPSIS θα μπορεί να προτείνει εξατομικευμένες συμβουλές αναφορικα με τη διατροφή, τη σωματική δραστηριότητα και τη διαχείριση του στρες, της κούρασης και του πόνου, με απώτερο σκοπό την υποστήριξη γιατρών, φροντιστών, και νοσοκομείων για την βέλτριστη διαχείριση της ψωριασική αρθρίτιδας. Τέλος, μέσω τεχνικών xAI, το iPROLEPSIS στοχεύει να διευκολύνει τα νοσοκομεία και τους υπεύθυνους χάραξης πολιτικής στην απόκτηση νέων γνώσεων για καλύτερες κλινικές πρακτικές, διαμορφώνοντας έτσι μελλοντικές πολιτικές θεραπείας PsA. Μεγιστοποίηση αντικτύπου Για να εξασφαλιστεί η επιτυχής υλοποίηση του πλάνου για τον μακροπρόθεσμο αντίκτυπο, η κοινοπραξία του έργου στοχεύει να κάνει το iPROLEPSIS σημείο αναφοράς για την καταπολέμηση της ψωριασικής αρθρίτιδας μέσω: 01 Δημιουργίας μίας ενεργής κοινότητας των ενδιαφερομένων μερών (κοινότητα iPROLEPSIS). 02 Ενημέρωση βασικών ενδιαφερομένων σχετικά με τα αποτελέσματα και τις δυνατότητες κλινικής καινοτομίας τους. 03 Κάνοντας τα προϊόντα ευρέως διαθέσιμα για ερευνητικούς και επιχειρηματικούς σκοπούς μακροπρόθεσμα. 04 Αύξησης της συμμετοχής ατόμων τα οποία είτε πάσχουν ή διατρέχουν κίνδυνο εκδήλωσης ψωριασικής αρθρίτιδας για την αντιμετώπιση των ζητημάτων και των ανησυχιών τους προκειμένου να αυξηθεί η ενημέρωση και η οικοδόμηση εμπιστοσύνης στη νέα τεχνολογία. 05 Επίτευξης παρόμοιων/σχετικών έργων Ε&Α για προώθηση της δικτύωσης και από κοινού δραστηριοτήτων. 06 Δημιουργίας φόρουμ/κοινότητας επαγγελματιών υγείας και συναφών αρχών για την ανάπτυξη νέων κατευθυντήριων γραμμών και προτύπων. 07 Προσδιορισμού μηχανισμών και δραστηριοτήτων εκμετάλλευσης, αξιολόγηση της εμπορευματικής αξίας και της εφαρμοσιμότητας των παραγόμενων εννοιών και ιδεών. ΣΤΟΧΟΙ ΤΟΥ ΕΡΓΟΥ

Σχετικά με τα μέλη της κοινοπραξίας Francisco Cardoso PLUX Position Software Developer What is your role in iPROLEPSIS? Monitoring Engineer What are your main activities in the project? I define SLIs/SLOs, design telemetry (metrics, logs, traces), build alerts and dashboards, run incident response/postmortems, and align data retention and security with compliance. What is your motivation? I’m motivated by making complex systems trustworthy. Turning real-time signals into fast decisions that reduce downtime and protect participants and data. Hugo Humberto Plácido da Silva PLUX Position Founder & Chief Innovation Officer What is your role in iPROLEPSIS? Principal Investigator representing PLUX. What are your main activities in the project? Internal management of the project at the board/administration level. Our team is making substantial contributions to the development of digital biomarkers (dBMs) that can be acquired using a smart belt. Furthermore, we are responsible for the iPROLEPSIS system orchestration, verification, and monitoring. What is your motivation? Psoriatic Arthritis (PsA) is a highly conditioning disease that currently affects a significant number of patients globally. Existing assessment and management methods are mostly bound to a clinical setting, involving complex protocols, therefore only of limited access to patients. For as long as I can remember, my work has been centered around purpose-driven innovations in the healthcare space; the possibility to explore novel dBMs as a way of improving the lives of PsA patients constitutes a once-in-a-lifetime opportunity and purpose like none other. Sofia Balula Dias Faculdade de Motricidade Humana Position Principal Investigator representing FMH partner What is your role in iPROLEPSIS? As Principal Investigator, I lead the design and development of a serious games-based intervention tool specifically tailored to support individuals living with Psoriatic Arthritis. What are your main activities in the project? Our multidisciplinary team is leading the development of the iPROLEPSIS serious games application to support Psoriatic Arthritis patients. Through co-creation with patients and collaboration across research, clinical, and design fields, we’re tailoring game mechanics and biofeedback features to meet real needs and preferences. Our work involves prototyping, testing, and refining therapeutic content designed to improve mobility, support pain management, reduce stress, and promote self-management, ultimately contributing to a more holistic and patient-centered approach to chronic care. What is your motivation? I am driven by the opportunity to improve the lives of PsA patients through non-pharmacological, technology-driven interventions. Serious games present an innovative and empowering method for symptom management and patient engagement. To date, there are no serious games specifically tailored to the needs of individuals with PsA, making this work both timely and impactful. Rodrigo Duarte Braga PLUX Position Research Collaborator What is your role in iPROLEPSIS? Systems Engineer What are your main activities in the project? I coordinate system orchestration, verification, and monitoring. I also lead the Smartbelt's technical development, from data acquisition and processing device data to building machine learning models. What is your motivation? Tackling complex challenges and developing innovative solutions and medical devices that create tangible value. Sérgio Lopes da Fonseca PLUX Position Project Manager What is your role in iPROLEPSIS? PLUX’s contribution to iPROLEPSIS management. What are your main activities in the project? Aligning timelines, deliverables, and resources across partners. I manage work-package commitments, budget and risks, and represent PLUX in steering and technical meetings to keep decisions action-oriented and on schedule. What is your motivation? To turn research into deployable, user-centred solutions. I’m driven by projects that measurably improve clinical workflows and patient outcomes—while creating a clear path from prototype to scalable product. iPROLEPSIS is a chance to do all three: integrate wearable biosignals seamlessly, prove value in real settings, and accelerate European med-tech competitiveness. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Managing Psoriatic Arthritis: Treatments and Lifestyle Handbook Handbook 2 How is psoriatic arthritis treated? While there is no cure for psoriatic arthritis, there are multiple drug treatment options that work to control the disease and its symptoms (3). Drug treatments specific for psoriatic arthritis focus on: DRUG TREATMENTS slowing down the progression of the condition; reducing inflammation; relieving pain; treating skin symptoms; keeping joints as mobile as possible. For most people, treatment for psoriatic arthritis will involve trying several different medications. Since many people with psoriatic arthritis have psoriasis, managing the condition can seem like treating two diseases. Some treatments work on both diseases, while others work mainly on the arthritis or skin problems. Every person diagnosed with psoriatic arthritis is different. Doctors recommend certain treatments depending on: how many and which parts of the body are affected; how severe the disease is; drug allergies and other health conditions; current medication use. Many times, people with psoriatic arthritis may need to take more than one drug at the same time to control the disease – this is called combination therapy. Combination therapy can allow for lower doses of each individual drug to be used. During flares, additional medications may be added temporarily or for the longer term.It is important to be involved in shared-decision making with your doctor(s) and adhere to the treatment plan. You should communicate any issues with medications, such as side effects or difficulty adhering to the treatment plan, so that effective steps can be taken to address the problem(s). TREATMENT FOR THE ARTHRITIS The over-the-counter and prescription medicines for psoriatic arthritis include: non-steroidal anti-inflammatory drugs (NSAIDs); steroid medication (corticosteroids); disease modifying anti-rheumatic drugs (DMARDs). See related Key Facts section h2.1 Non-steroidal anti-inflammatory drugs (NSAIDs) NSAIDs can help relieve pain and reduce inflammation, but they might not be enough to treat symptoms of psoriatic arthritis (9). There are two types of NSAIDs: traditional NSAIDs, such as ibuprofen, naproxen, and diclofenac; COX-2 inhibitors, such as celecoxib and etoricoxib. Like all medicines, NSAIDs can have side effects. Your doctor will take precautions to reduce the risk of side effects by prescribing the lowest dose necessary to control your symptoms for the shortest time possible. NSAIDs can sometimes affect the stomach and intestines, causing digestive problems such as indigestion and stomach ulcers (17). A medication called a proton pump inhibitor (PPI), such as omeprazole or lansoprazole, may also be prescribed to help protect the stomach. Chronic treatment with NSAIDs can also increase the risk of heart attacks, strokes, and other heart problems (17). Please, let your doctor know if there are risk factors that may increase your overall risk, for example, smoking, high blood pressure, high cholesterol, diabetes, or a family history of heart disease. Some people have found that taking NSAIDs made their psoriasis symptoms worse. Inform your doctor if this happens to you. Steroid medication (corticosteroids) Like NSAIDs, corticosteroids can help reduce inflammation and pain (18). If you have a single painful and/or swollen joint, your doctor may inject the medication directly into the joint. The effect can last from a few weeks to several months. However, having too many steroid injections in the same joint(s) can damage the surrounding tissue and, thus, your doctor will usually not recommend more than three injections per year. When lots of joints are inflamed, corticosteroids can be taken as a tablet, or as an injection into the muscle. However, doctors are cautious about this because corticosteroids can cause side effects, such as weight gain and osteoporosis, increased risk of infection and cardiovascular events, if used for long periods of time. Because of these side effects, your doctor will prescribe you the lowest dose necessary to control your symptoms for the shortest time possible. Psoriasis can flare up when you stop using oral corticosteroids. Disease modifying anti-rheumatic drugs (DMARDs) DMARDs are powerful medications that reduce inflammation and can stop psoriatic arthritis from getting worse (19). DMARDs can help prevent damage to your joints. Many DMARDs will treat both psoriasis and psoriatic arthritis. Because this type of medicine treats the cause of your condition and not the symptoms, it can take up to three months before you feel an effect. Therefore, it is important to keep taking the medication, even if it does not seem to be working at first. Like all drugs, DMARDs can have some side effects. While DMARDs can be very effective, these medications reduce the activity of the immune system (immunosuppressants) and raise the risk of an infection. However, it is important to remember that not treating psoriatic arthritis could lead to permanent bone and joint damage. There are three types of DMARDs as described in Table 1. Table 1: Types of disease modifying anti-rheumatic drugs. Traditional Traditional DMARDs (csDMARDs) have been used the longest and have a broad immune- suppressing effect. These medicines are usually taken by mouth. Example: methotrexate, sulfasalazine. Biologic Biologic DMARDs (bDMARDs) disrupt key steps in the inflammatory process and generally work more quickly than traditional DMARDs. These drugs are usually injected. Example: adalimumab, etanercept. Targeted Like biologic DMARDs, targeted DMARDs (tsDMARDs) block key steps in the inflammatory process. These medications are usually taken by mouth. Example: tofacitinib. TREATMENT FOR THE PSORIASIS The over-the-counter and prescription medicines for psoriasis include: topical medications made from vitamin D, derivatives of vitamin A, salicylic acid, coal tar or corticosteroids; phototherapy that uses ultraviolet light (UVB) may be prescribed to treat and lessen skin rashes. Only your doctor should prescribe phototherapy, do not try to use sunlight or sunlamps to treat your skin on your own; some DMARDs and biological therapies used for arthritis can also help the psoriasis. VACCINES If you have psoriatic arthritis, you may have a higher risk of infection and infections may be more severe (20). This can be due to the arthritis itself or its treatment. Psoriatic arthritis, which caused by a fault of the immune system, can make you more vulnerable to infections. In addition, some of the drugs utilised to treat psoriatic arthritis (e.g., DMARDs and/ or steroids) dampen down the immune system, that is, they act as immunosuppressants, which can also make you more prone to infection. An increased risk of infection due to a medical condition and/or drugs is called immunosuppression. Your rheumatologist can provide guidance based on your age and your risk for getting certain infectious diseases (e.g., COVID-19, flu, pneumonia, shingles, or hepatitis B). Vaccines are safe and can help you avoid serious infections. See related Key Facts section Non-pharmacological treatments NON-PHARMACOLOGICAL TREATMENTS Drugs are not the only way to treat or manage the symptoms of psoriatic arthritis. There are many things you can do, alongside taking prescribed medication, that can improve your life quality by lessening pain and inflammation, and improving your overall health. YOUR VOICE MATTERS Your experiences – how your therapies are working, what side affects you are experiencing, how your symptoms are affecting you, what challenges you are facing in your daily life due to psoriatic arthritis – are very important pieces of information. This information is called patient-reported outcomes (PROs) and it may be collected via a questionnaire prior to your rheumatology appointment. PROs can help your doctor assess the impact of your disease and better evaluate your treatment plan. These questionnaires can also help you self-manage your condition. Some of the questionnaires your rheumatologist may use are: PSAID (Psoriatic Arthritis Impact of Disease): measures the impact of your disease on your physical and psychological health; VAS (Visual Analogue Scale): a simple tool to track and measure your pain; IPAQ (International Physical Activity Questionnaire): measures the types of intensity of physical activity and sitting time that people do as part of their daily lives; HAQ (Health Assessment Questionnaire): measures your physical function and disability due to arthritis; FACIT-F (Functional Assessment of Chronic Illness Therapy - Fatigue): measures your fatigue that is caused by the arthritis; WPAI (Work Productivity and Activity Impairment): measures impairments in work and activities; HADS (Hospital Anxiety and Depression Scale): measures the levels of anxiety and depression; PsAQoL (Psoriatic Arthritis Quality of Life): measures the quality of life in people with psoriatic arthritis; EQ-5D (EuroQol-5 Dimensions): measures quality of life in relation to 5 dimensions – mobility, usual activities, self-care, pain and discomfort, and anxiety and depression; SF-36 (Short Form-36): measures quality of life and covers 8 domains of health – physical functioning, physical role, pain, general health, vitality, social function, emotional role, and mental health. So, if your doctor or nurse asks you to fill out a questionnaire, please take the time to do it and be honest! PHYSICAL AND OCCUPATIONAL THERAPY Inflammation of joints and soft tissues can often lead to extreme pain, immobility, and dysfunction. Additionally, the arthritis can lead to difficulty in daily activities in the home and workplace. Physical and occupational therapy can help you get moving safely and effectively. Physical therapy is the most impactful if you are experiencing (21): loss of motion due to inflammation in the shoulder, wrist, hand, knee, or foot; severe enthesitis or dactylitis; inflammatory back pain. Physical therapy will focus on (21): improving mobility and restore the use of affected joints; increasing muscle strength to support the joints; maintaining fitness; preserving the ability to perform daily activities. Occupational therapy can also be helpful, especially if you are experiencing difficulties with everyday activities. See related Key Facts section h2.3 Occupational therapy can help you maximise your ability to participate in daily activities. Strategies include the use of assistive devices (e.g., braces, splints), and movement modification to help people protect their joints by performing tasks in different ways than they are used to (e.g., using both hands). SURGERY Most people diagnosed with psoriatic arthritis will never need joint surgery. However, if joints are severely damaged by the arthritis, or if other treatments do not reduce pain, damaged joints can be replaced by plastic, metal, or ceramic prosthesis to reduce pain, and improve function and quality of life. COMPLEMENTARY TREATMENTS Some people with psoriatic arthritis feel that complementary therapies can be helpful. However, you should always talk to your doctor before trying complementary therapies. There is no scientific evidence to support that taking any kind of dietary supplement, such as fish body oil capsules, works in treating psoriatic arthritis. In addition, there is not enough scientific evidence to support the use of complementary therapies, such as balneotherapy or acupuncture, as treatments for psoriatic arthritis. Complementary therapies can react with other treatments, so you should talk to your doctor if you are using or thinking of using any. See related Key Facts section SELF-CARE AND LIFESTYLE Sedentary behaviour Sedentary behaviour, characterised by prolonged periods of sitting, when accumulated daily for more than 8 hours or maintained for periods longer than 30 minutes without interruption, constitutes a risk to health and well-being. h2.4 h2.5 Since mechanical stress in the case of an inflammatory crisis can promote the appearance of enthesitis, it is necessary to control inflammation before increasing the level of usual physical activity or starting an exercise programme. In any case, the beneficial effects of physical activity and exercise on disease, well-being and associated comorbidities outweigh the risk of enthesitis induced by mechanical stress, which is low (25). Diet While there is no a specific diet that can treat psoriatic arthritis, adopting a nutritious and balanced eating plan can play a vital role in managing symptoms and improving overall wellbeing. Research suggests that adopting a Mediterranean-style diet (Figure 3, left-hand side), which includes fruits, vegetables, fibre, high-quality fats, and vitamins, might lessen the impact of your psoriatic arthritis (26). This type of diet has anti-inflammatory benefits that help manage disease activity. So, trying this eating approach might help you ease your psoriatic arthritis symptoms. Incorporating omega-3 fatty acids , commonly found in oily fish (such as salmon, mackerel, or flaxseeds), can also have anti-inflammatory effects, potentially reducing joint stiffness and tenderness (27). Antioxidants found in colourful fruits and vegetables (such as berries, spinach, and kale) also offer potent anti-inflammatory properties that could alleviate joint inflammation and discomfort in people living with psoriatic arthritis. Overall, it is recommended to aim for a balanced intake of 2-5 portions of fruits and 3-5 portions of vegetables daily, as these nutrient-rich foods provide essential antioxidants that may contribute to managing joint inflammation and overall health. Figure 3: Beneficial (on the left side) and harmful (on the right side) dietary patterns. Adapted from Guilliams et al., 2023 (28). Reducing the intake of sugar, saturated fats , and sodium can help you maintain a healthy weight. Obesity is linked to a higher chance of developing psoriatic arthritis, underlining the significance of weight management, especially for psoriasis patients who often suffer from metabolic syndrome and obesity (29). In people living with psoriatic arthritis, studies suggest that sedentary behaviour may contribute to increased joint stiffness, reduced muscle strength, and compromised joint function. Additionally, a sedentary lifestyle may exacerbate symptoms such as fatigue and depression, which are common in psoriatic arthritis. While the exact mechanisms are not fully understood, maintaining an active lifestyle is generally considered beneficial for managing psoriatic arthritis symptoms. The risks of sedentary behaviour increase even more when people are inactive; that is, they do not comply with the World Health Organization’s (WHO) recommendations for physical activity, described below. Physical activity Engaging in regular physical activity has been shown to have numerous benefits for people living with psoriatic arthritis. Physical activity concerns all body movements resulting from muscle contraction regardless of the context in which they are carried out: leisure, transportation to and from places, or as part of a person’s work. Physical activity can help improve joint flexibility, reduce inflammation, and enhance overall joint function. Moreover, physical activity may contribute to better mental health, as it can help alleviate symptoms of depression and anxiety that are often associated with chronic conditions like psoriatic arthritis. Physical activity also plays a role in weight management, which is essential as excess weight can increase joint stress (22). According to the WHO, it is recommended to accumulate at least ~20 minutes per day of physical activity, such as brisk walking (23). This recommendation is also adopted by the European Alliance of Associations for Rheumatology (24). A 20-minute physical activity of moderate intensity corresponds to an accumulation of around 2000 steps. Considering a functional activity of 4500 steps per day associated with carrying out activities of daily living such as grooming, cooking, cleaning, travelling to and from work/school, the WHO recommendations, when expressed in total number of steps per day, represent the sum of the two types of activity and correspond to an accumulation of 6500 daily steps under normal living conditions. Physical exercise The most beneficial types of exercise for psoriatic arthritis focus on improving flexibility, strength, and cardiovascular fitness without causing excessive joint stress. Low-impact activities such as swimming, walking, and cycling are often recommended. Strength training exercises, including resistance training and gentle yoga, can help enhance muscle support around the joints. Water-based exercises are particularly advantageous as they provide buoyancy, reducing impact on the joints. The benefits of these exercises include increased joint mobility, reduced pain and stiffness, improved muscle tone, and better overall well-being. People living with psoriatic arthritis should adopt a tailored physical activity routine, considering their specific symptoms and limitations. The iPROLEPSIS app intends to help you limit sedentary behaviours, increase physical activity, and improve daily functional capacity with specific and safe training program recommendations (for more information see section “iPROLEPSIS”). Excess weight can increase joint discomfort and inflammation, particularly in load-bearing joints (such as the hips, knees, and spine). Thus, be mindful of your dietary choices, as these can help you manage your symptoms. Vitamin D aids in calcium absorption, which is necessary for maintaining healthy bones. Additionally, vitamin D helps boost our immune system, fight off viruses, and combat fatigue. It has even been linked to good mood, with a deficiency potentially leading to anxiety and depression. Vitamin D is a fat-soluble vitamin that our bodies produce when the skin is exposed to sunlight. It can also be obtained from certain foods or supplements. This vitamin has several forms, but the most important ones are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D3 is the form that our skin produces naturally in response to sunlight. Research indicates that people with psoriatic arthritis often have lower vitamin D levels than others (30). Having enough vitamin D might help ease some psoriatic arthritis symptoms. The best way to ensure this is through adequate sun exposure. Spending around 10 to 30 minutes in the sun between 10 AM and 3 PM, at least twice a week, is generally sufficient for most individuals to produce enough vitamin D. The exact time needed depends on factors such as skin type, latitude, altitude, and season. The Medical Board of the National Psoriasis Foundation recommends vitamin D supplementation for psoriatic arthritis patients and encourages overweight or obese patients to explore weight reduction through a controlled diet (31). However, you must seek advice from your doctor. Hydration is another key aspect often overlooked, but crucial in managing psoriatic arthritis. Though there are no specific hydration guidelines for people with psoriatic arthritis, drinking around two litres of water daily not only supports maintaining overall health (32), but also helps in joint lubrication and efficient functioning, easing discomfort associated with movement. Some individuals find that certain foods may trigger or exacerbate their psoriatic arthritis symptoms. While these triggers can vary among individuals, common contributors include red and processed meat, low-quality fats, salt and additives, and refined carbohydrates (Figure 3 ; right-hand side). Monitoring your diet and identifying potential trigger foods through a systematic dietary approach or under the guidance of a healthcare professional can help manage pain, fatigue, and flare-ups (33). It is essential to find guidance from a healthcare provider or a dietitian with expertise in psoriatic arthritis to develop a personalised dietary plan (28) aligned with individual preferences and needs. A personalised plan aims to guarantee sufficient nutrient intake, manage weight, and promote overall well-being, addressing the unique challenges associated with psoriatic arthritis. Moreover, embracing a healthy lifestyle, including consistent physical activity, stress management, and a well-balanced diet, holds significant potential to improve the quality of life for people with psoriatic arthritis. Smoking and alcohol consumption Smoking is bad for your overall health, as it increases the likelihood of potential complications, such as heart problems and cancer. Smoking can also make you less sensitive to treatment and worsen your psoriasis symptoms (34, 35). Alcohol can interfere with the effectiveness of some drugs or increase side effects (36, 37). Some studies also suggest that alcohol may act as a trigger for flare-ups (38). See related Key Facts section See related Key Facts Previous page Next page

Learn more about international events for psoriatic arthritis. Choose the event and book the date. Επικείμενο και παρελθόν εκδηλώσεις iPROLEPSIS 7th Plenary meeting 09 Δεκ 2025, 9:00 π.μ. – 10 Δεκ 2025, 4:00 μ.μ. Lisbon, Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία IEEE HealthCom 2025 21 Οκτ 2025, 9:00 π.μ. – 7:30 μ.μ. Abu Dhabi, United Arab Emirates Περισσότερες πληροφορίες Στοιχεία HLTH Event 2025 19 Οκτ 2025, 9:00 π.μ. – 22 Οκτ 2025, 6:00 μ.μ. Las Vegas, Las Vegas, NV, USA Περισσότερες πληροφορίες Στοιχεία GRAPPA Annual Meeting 2025 10 Ιουλ 2025, 11:00 π.μ. – 12 Ιουλ 2025, 8:00 μ.μ. Bogota, Colombia Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 6th Plenary meeting 13 Μαΐ 2025, 11:00 π.μ. – 14 Μαΐ 2025, 5:00 μ.μ. Oxford, UK Περισσότερες πληροφορίες Στοιχεία 7th Polythematic Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology 28 Μαρ 2025, 10:00 π.μ. – 30 Μαρ 2025, 8:00 μ.μ. Portaria, Pelion Περισσότερες πληροφορίες Στοιχεία Health Data Summit 2025 19 Μαρ 2025, 9:00 π.μ. – 20 Μαρ 2025, 7:00 μ.μ. The EGG, Brussels, Belgium Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 5th Plenary Meeting 02 Δεκ 2024, 7:00 π.μ. – 03 Δεκ 2024, 5:00 μ.μ. Athens, Greece Περισσότερες πληροφορίες Στοιχεία DSAI 2024 13 Νοε 2024, 7:00 π.μ. – 15 Νοε 2024, 5:00 μ.μ. Khalifa University, Abu Dhabi, United Arab Emirates (UAE) Περισσότερες πληροφορίες Στοιχεία PhD Open Days 2024 - 10th edition 05 Νοε 2024, 7:00 μ.μ. – 11:00 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία How to communicate about and disseminate project results under Horizon Europe Cluster 1 ‘Health’ and Horizon 2020 24 Οκτ 2024, 12:00 μ.μ. – 1:00 μ.μ. EEST Webinar Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 2nd Plenary meeting (1) 05 Οκτ 2024, 8:00 π.μ. – 06 Οκτ 2024, 6:00 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 2nd Plenary meeting (1) 28 Σεπ 2024, 8:00 π.μ. – 11:50 μ.μ. Virtual Περισσότερες πληροφορίες Στοιχεία European Researchers’ Night 27 Σεπ 2024, 8:00 π.μ. – 7:40 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία InnoHealth Forum 2024 20 Σεπ 2024, 8:00 π.μ. – 21 Σεπ 2024, 6:00 μ.μ. Larissa, Greece Περισσότερες πληροφορίες Στοιχεία IEEE EMBC 2024 15 Ιουλ 2024, 8:00 π.μ. – 19 Ιουλ 2024, 6:00 μ.μ. Orlando, Florida, USA Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 4th Plenary meeting 01 Ιουλ 2024, 8:00 π.μ. – 02 Ιουλ 2024, 6:00 μ.μ. Munich, Germany Περισσότερες πληροφορίες Στοιχεία IFPA Conference 2024 27 Ιουν 2024, 8:00 π.μ. – 29 Ιουν 2024, 4:00 μ.μ. Stockholm, Sweden Περισσότερες πληροφορίες Στοιχεία Φόρτωση περισσοτέρων

Download needed promo materials for iProlepsis project for psoriatic arthritis, such as posters, flyers, logos, and color palete. Προωθητικό υλικό για λήψη 01 Αφίσα iPROLEPSIS (A0) 02 Φυλλάδιο iPROLEPSIS (A5) 03 iPROLEPSIS Roll-up αφίσα Λογότυπο και χρωματική παλέτα για να κατεβάσετε PNG, διαφανές φόντο SVG, διαφανές φόντο SVG, διαφανές φόντο #212178 #B380FF #FFAACC #37C8AB #DEEBF7 PNG, λευκό φόντο WEBP, διαφανές φόντο

Read publications about iProlepsis project for psoriatic arthritis. Discover insights and project progress. Εκδόσεις έργου iPROLEPSIS European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis 19 Μαΐου 2025 The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read More Developing Sensorimotor Art Games for Psoriatic Arthritis using Agile Storyboarding and Game Co-Design Processes 28 Ιουνίου 2024 Serious Games (SGs) have the potential to provide clinical care and enhance patients’ quality of life, while incorporating an element of entertainment. As part of the iPROLEPSIS Horizon Europe project, we introduce two Sensorimotor Art games designed as SGs to assist Psoriatic Arthritis (PsA) patients in managing their symptoms. Read More Can ChatGPT provide appropriate meal plans for NCD patients? 30 Μαΐου 2024 Dietary habits significantly affect health conditions and are closely related to the onset and progression of non-communicable diseases (NCDs). Consequently, a well-balanced diet plays an important role in lessening the effects of various disorders, including NCDs. Read More Federated Learning Aggregation based on Weight Distribution Analysis 3 Οκτωβρίου 2023 Federated learning has recently been proposed as a solution to the problem of using private or sensitive data for training a central deep model, without exchanging the local data. Read More Hot topic debate: preventing psoriatic arthritis in patients with psoriasis 11 Νοεμβρίου 2024 Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read More “The Kite” Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis 27 Ιουνίου 2024 Serious Games (SGs) have been explored in healthcare for their potential as gamified means for disease assessment and/or intervention. Designing effective SGs requires attention to user requirements and iterative development. We introduce a SG design process for Psoriatic Arthritis (PsA) patients, aiming to enhance their quality of life. Read More AI nutrition recommendation using a deep generative model and ChatGPT 31 Μαΐου 2024 In recent years, major advances in artificial intelligence (AI) have led to the development of powerful AI systems for use in the field of nutrition in order to enhance personalized dietary recommendations and improve overall health and well-being. Read More Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers 30 Οκτωβρίου 2024 The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Read More ChatGPT in Nutrition: Trends Challenges and Future Directions 26 Ιουνίου 2024 A healthy and balanced diet is of paramount importance to the physical and psychological well-being of an individual, since unhealthy dietary choices have been linked with the occurrence of non-communicable diseases. Read More Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes 26 Ιουνίου 2024 Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Read More